Abstract library

22 results for "glucagonoma".
#1108 Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection
Introduction: Glucagonomas-associated ocular manifestations have been exceptionally reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lucie Defour
#1063 Hypoglycaemia in a Patient with Glucagonoma-Coincidence of a Glucagonoma and Insulinoma in a Patient with Multiple Endocrine Neoplasia Type I
Introduction: We report the case of a 54 year old female with a known MEN1 syndrome with primary Hyperparathyroidism, a Prolactinoma and a pancreatic tumor. The patient complains about episodes of fatigue and sweating, both symptoms improve immediately after a meal.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Vinzenz Stepan
Authors: Ploner F, Plank J, Humer-Fuchs U, Lax S, ...
Keywords: MEN1, Glucagonoma
#996 Good Clinical Response to a Somatostatin Analog in a Patient with Metastatic Glucagonoma and Necrolytic Migratory Erythema: 5-Year Follow-Up
Introduction: Glucagonoma is a rare neuroendocrine tumor of the pancreas usually diagnosed in advanced stages or when necrolytic migratory erythema occurs.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Lisseth F Marín
#1511 MEN1-related Glucagonomatosis Incidentally Revealed During Management of Recurrent Intestinal Obstruction Following Surgery for Crohn’s Disease
Introduction: Glucagonomas may present with varied intestinal symptoms,weight loss,diabetes and a typical rash. MEN1 related glucagonomas are extremely rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD, PhD Student Anna Malczewska
Keywords: MEN1, glucagonoma
#232 Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)
Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Elena Martin-Perez
#691 Pancreatic Focal Alpha Cell Hyperplasia with Hyperglucagonaemia without the Glucagonoma Syndrome
Introduction: Pancreatic alpha cell hyperplasia and hyperglucagonaemia without the glucagonoma syndrome is a rare clinical syndrome not widely recognised. Here we describe a novel mutation in the glucagon receptor gene (GCGR) in a patient with the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Helen Miller
Authors: Miller H, Baird D, Kidd M, Cohen P, ...
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics
Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#134 Gastrointestinal neuroendocrine tumors: tumor characteristics and long-term clinical outcome in the German NET registry
Introduction: Prognosis of neuroendocrine tumors (NETs) has been difficult to predict due to heterogenous tumor biology, various classification systems, and lack of reliable and recent data due to the rarity of these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Ulrich-Frank Pape
Authors: Maasberg S, König A, Rinke A, Anlauf M, ...